EVIDENCE LIBRARY
Benzodiazepine history and laboratory-confirmed infection in a low-incidence regional cohort
A Spanish first-wave study examined detected infection rather than death or laboratory susceptibility to a virus.
A Spanish first-wave study examined detected infection rather than death or laboratory susceptibility to a virus.
What the cohort measured
The Tarragona analysis related baseline conditions and medication histories to laboratory-confirmed SARS-CoV-2 infection. Recorded benzodiazepine use had an adjusted hazard ratio of 1.24, with a confidence interval from 1.00 to 1.53.
The estimate was modest and close to the null boundary. The outcome depended on detected infection in a particular early-pandemic setting, not a controlled viral challenge or direct measurement of immune impairment.
Detection and causation are separate
Testing access, healthcare contact, residence, comorbidity, and unmeasured factors may influence both medication records and detection. An observational association cannot determine that benzodiazepines increased biological susceptibility.
The geographical area had relatively low incidence, limiting extrapolation to other epidemic conditions. For evidentiary use, preserve the infection endpoint and the uncertainty interval. The study does not establish why one person became infected or support a causal conclusion from a prescription history alone.
Source paper
Original analysis of the supplied journal article, identified as PMC8103142.